Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gonadotropin + cetrorelix
- Development stage
- Unknown
- Lead developer
- Tanta University
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This combination therapy, referred to as the **ANTIUI protocol** in clinical research led by **Tanta University**, involves the co-administration of exogenous gonadotropins and the gonadotropin-releasing hormone (GnRH) antagonist **cetrorelix**. Cetrorelix is a synthetic decapeptide that functions as a competitive antagonist of the GnRH receptor in the pituitary gland. By blocking these receptors, it rapidly suppresses the secretion of endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing premature LH surges and unintended ovulation. The gonadotropin component (such as FSH or HMG) is administered to stimulate the development and maturation of multiple ovarian follicles. This specific regimen is investigated for its potential to improve ovulation and pregnancy rates in patients with unexplained infertility undergoing intrauterine insemination (IUI) by providing enhanced control over the ovulatory cycle.
- Brand names
- Cetrotide
- Other names
- ANTIUI protocolcetrorelix acetate
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on gonadotropin + cetrorelix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gonadotropin + cetrorelix.